These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 33217413)

  • 1. Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.
    Schwalk AJ; Ost DE; Saltijeral SN; De La Garza H; Casal RF; Jimenez CA; Eapen GA; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee J; Elamin Y; Zhang J; Roth JA; Swisher S; Heymach JV; Grosu HB
    Chest; 2021 Mar; 159(3):1256-1264. PubMed ID: 33217413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for pleural effusion recurrence in patients with malignancy.
    Grosu HB; Molina S; Casal R; Song J; Li L; Diaz-Mendoza J; Reddy C; Yarmus L; Schiavo D; Simoff M; Johnstun J; Raid AA; Feller-Kopman D; Lee H; Sahetya S; Foley F; Maldonado F; Tian X; Noor L; Miller R; Mudambi L; Saettele T; Vial-Rodriguez M; Eapen GA; Ost DE
    Respirology; 2019 Jan; 24(1):76-82. PubMed ID: 29966171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.
    Yao Y; Peng M; Shen Q; Hu Q; Gong H; Li Q; Zheng Z; Xu B; Li Y; Dong Y
    Thorac Cancer; 2019 Feb; 10(2):193-202. PubMed ID: 30565433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for symptomatic malignant pleural effusion recurrence in patients with actionable mutations in advanced lung adenocarcinoma.
    Xu K; Wu X; Chen L; Xie J; Hua X; Chen M; Jiang Y; Liu H; Zhang F; Lv T; Song Y; Zhan P
    Transl Lung Cancer Res; 2023 Sep; 12(9):1887-1895. PubMed ID: 37854163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of early definitive management for newly diagnosed malignant pleural effusion related to lung cancer.
    Chiang KY; Ho JC; Chong P; Tam TC; Lam DC; Ip MS; Lee YG; Lui MM
    Respirology; 2020 Nov; 25(11):1167-1173. PubMed ID: 32249488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of bevacizumab through an indwelling pleural catheter in non-small cell lung cancer patients with symptomatic malignant pleural effusion.
    Zeng H; Zhang Y; Tan S; Huang Q; Pu X; Tian P; Li Y
    BMC Pulm Med; 2024 Feb; 24(1):89. PubMed ID: 38365707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Clinical and Economic Implications of Different Treatment Pathways for Patients With Rapidly Recurrent Malignant Pleural Effusion.
    Ost DE; Goldblatt C; Jung M; Weiss M; Xu S; Taneja A; Erdal E
    Chest; 2024 Oct; 166(4):867-881. PubMed ID: 38838953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of thoracic tumor radiotherapy on survival in non-small-cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study.
    Li Q; Hu C; Su S; Ma Z; Geng Y; Hu Y; Jin H; Li H; Lu B
    Cancer Med; 2023 Jul; 12(14):14949-14959. PubMed ID: 37288833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments in pleurodesis for malignant pleural disease.
    Guinde J; Georges S; Bourinet V; Laroumagne S; Dutau H; Astoul P
    Clin Respir J; 2018 Oct; 12(10):2463-2468. PubMed ID: 30252207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma.
    Verma A; Chopra A; Lee YW; Bharwani LD; Asmat AB; Aneez DB; Akbar FA; Lim AY; Chotirmall SH; Abisheganaden J
    Curr Drug Discov Technol; 2016; 13(2):68-76. PubMed ID: 27216707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph nodes rather than pleural metabolic activity in
    Jiang Y; Liu T; Xu K; Cheng Q; Lu W; Xie J; Chen M; Li Y; Du Y; Liang S; Song Y; Wu J; Lv T; Zhan P
    Transl Lung Cancer Res; 2024 Sep; 13(9):2236-2253. PubMed ID: 39430341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical course of asymptomatic malignant pleural effusion in non-small cell lung cancer patients: A multicenter retrospective study.
    Roh J; Ahn HY; Kim I; Son JH; Seol HY; Kim MH; Lee MK; Eom JS
    Medicine (Baltimore); 2021 May; 100(19):e25748. PubMed ID: 34106603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.
    Ren S; Terman DS; Bohach G; Silvers A; Hansen C; Colt H; Sahn SA
    Chest; 2004 Nov; 126(5):1529-39. PubMed ID: 15539723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary best practice in the management of malignant pleural effusion.
    Koegelenberg CFN; Shaw JA; Irusen EM; Lee YCG
    Ther Adv Respir Dis; 2018; 12():1753466618785098. PubMed ID: 29952251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
    Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
    Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant pleural effusion cell blocks are substitutes for tissue in EML4-ALK rearrangement detection in patients with advanced non-small-cell lung cancer.
    Zhong J; Li X; Bai H; Zhao J; Wang Z; Duan J; An T; Wu M; Wang Y; Wang S; Wang J
    Cytopathology; 2016 Dec; 27(6):433-443. PubMed ID: 27060609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non-small-cell lung cancer.
    Zhang X; Wang X; Wen Y; Chen S; Zhou C; Wu F
    Clin Transl Med; 2024 Apr; 14(4):e1649. PubMed ID: 38629624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of pleural fluid carcinoembryonic antigen on therapeutic strategy and efficacy in lung adenocarcinoma patients with malignant pleural effusion.
    Lee J; Lee DH; Park JE; Lee YH; Choi SH; Seo H; Yoo SS; Lee SY; Cha SI; Park JY; Kim CH
    Korean J Intern Med; 2024 Mar; 39(2):318-326. PubMed ID: 38351680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.
    Morgensztern D; Waqar S; Subramanian J; Trinkaus K; Govindan R
    J Thorac Oncol; 2012 Oct; 7(10):1485-9. PubMed ID: 22982649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non-small-cell lung cancer.
    Zhou J; Yao H; Zhao J; Zhang S; You Q; Sun K; Zou Y; Zhou C; Zhou J
    Histopathology; 2015 Jun; 66(7):949-54. PubMed ID: 25257756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.